Immutep

IMMP

Market cap $88.8M

New York, New York--(Newsfile Corp. - April 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from allegations that Immutep may have issued materially misleading business information to the investing public.

NEW YORK, April 20, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from allegations that Immutep may have issued materially misleading business information to the investing public.

NEW YORK, April 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from allegations that Immutep may have issued materially misleading business information to the investing public.

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from allegations that Immutep may have issued materially misleading business information to the investing public.

Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases.

Immutep Stock Collapsed Up to 90% After Independent Committee Recommended Halting Lead Phase III Trial -- Levi & Korsinsky Investigates Potential Securities Law Violations NEW YORK, April 15, 2026 /PRNewswire/ -- Immutep Ltd. (NASDAQ: IMMP) shares lost approximately 80% to 90% of their value after the company disclosed that an Independent Data Monitoring Committee (IDMC) recommended halting the Phase III TACTI-004 trial of eftilagimod alfa in first-line non-small-cell lung cancer because an interim futility analysis showed the drug was unlikely to meet its efficacy endpoints.

SYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for eftilagimod alfa (“efti”) for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need.

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, April 14, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from allegations that Immutep may have issued materially misleading business information to the investing public.